Thursday, October 15, 2026
ExploreSearch
Finance Via News

Venture Capital & Private Equity

2 articles

Venture Capital Reclaims Mega-Round Leadership as Tiger Global, SoftBank Pull Back 95%

Venture Capital Reclaims Mega-Round Leadership as Tiger Global, SoftBank Pull Back 95%

Traditional venture capital firms have regained control of $50M+ financing rounds after Tiger Global Management and SoftBank Vision Fund cut their deal count by over 95% since 2021. The 2025 market saw 1,440 companies raise mega-rounds—half the 2021 total—with established VCs capitalizing on AI-wave opportunities while mega-investors retreat from overheated valuations.

ViaNews Editorial Team (Finance)•
Traditional VC Firms Reclaim 80% of $50M+ Deals as Tiger Global, SoftBank Retreat 95%

Traditional VC Firms Reclaim 80% of $50M+ Deals as Tiger Global, SoftBank Retreat 95%

Pure venture capital firms now lead 8 of 10 funding rounds above $50 million, reclaiming dominance from mega-investors who flooded the market in 2021. Tiger Global and SoftBank Vision Fund cut their deal activity by over 95% since peak deployment. The shift marks a return to specialized venture expertise as tourist capital exits.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com